Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/ijms22126607 http://scihub22266oqcxt.onion/10.3390/ijms22126607 34205487!8234423!34205487     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Mol+Sci 2021 ; 22 (12): ä Nephropedia Template TP {{tp|p=34205487|t=2021. Inflammatory Mechanisms in COVID-19 and Atherosclerosis: Current Pharmaceutical Perspectives |pdf=|usr=}}{{34205487}} gab.com Text Inflammatory Mechanisms in COVID-19 and Atherosclerosis: Current Pharmaceutical Perspectives JO: Int J Mol Sci http://www.kidney.de/pget.php?&tw=1&pmid=34205487 #FOAvip Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been associated with excess mortality worldwide. The cardiovascular system is the second most common target of SARS-CoV-2, which leads to severe complications, including acute myocardial injury, myocarditis, arrhythmias, and venous thromboembolism, as well as other major thrombotic events because of direct endothelial injury and an excessive systemic inflammatory response. This review focuses on the similarities and the differences of inflammatory pathways involved in COVID-19 and atherosclerosis. Anti-inflammatory agents and immunomodulators have recently been assessed, which may constitute rational treatments for the reduction of cardiovascular events in both COVID-19 and atherosclerotic heart disease. Twit Text FOAVip Inflammatory Mechanisms in COVID-19 and Atherosclerosis: Current Pharmaceutical Perspectives ????Int J Mol Sci http://www.kidney.de/pget.php?&tw=1&pmid=34205487 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34205487 #FOAvip English Wikipedia <ref>{{Cite pmid|34205487}}</ref> Inflammatory Mechanisms in COVID-19 and Atherosclerosis: Current Pharmaceutical Perspectives #MMPMID34205487 Sagris M; Theofilis P; Antonopoulos AS; Tsioufis C; Oikonomou E; Antoniades C; Crea F; Kaski JC; Tousoulis D Int J Mol Sci 2021[Jun]; 22 (12): ä PMID34205487show ga Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been associated with excess mortality worldwide. The cardiovascular system is the second most common target of SARS-CoV-2, which leads to severe complications, including acute myocardial injury, myocarditis, arrhythmias, and venous thromboembolism, as well as other major thrombotic events because of direct endothelial injury and an excessive systemic inflammatory response. This review focuses on the similarities and the differences of inflammatory pathways involved in COVID-19 and atherosclerosis. Anti-inflammatory agents and immunomodulators have recently been assessed, which may constitute rational treatments for the reduction of cardiovascular events in both COVID-19 and atherosclerotic heart disease. |Adrenal Cortex Hormones/therapeutic use[MESH] |Anti-Inflammatory Agents/therapeutic use[MESH] |Atherosclerosis/complications/drug therapy/*pathology/prevention & control[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19/complications/*pathology/virology[MESH] |Chemokines/metabolism[MESH] |Cytokine Release Syndrome/etiology[MESH] |Cytokines/metabolism[MESH] |Humans[MESH] |Prognosis[MESH]Inflammatory Mechanisms in COVID-19 and Atherosclerosis: Current Pharm(epmc).pdf DeepDyve Pubget Overpricing